Leonard Reyno

Company: Pionyr Immunotherapeutics

Job title: Executive Vice President & Chief Medical Officer

Seminars:

Industry Leader’s Fireside Chat: A Roundup of Clinical Development with a Focus on Clinical Validation 9:30 am

• Unraveling clinical success stories to reaffirm the potential of macrophage-directed therapies and boost investment in the macrophage space • Addressing key dosing, safety, and efficacy challenges to accelerate clinical resultsRead more

day: Day Two

PY314: Targeting Trem2 Positive Macrophages in Patients with Advanced Solid Tumors 9:00 am

• TREM2 is highly expressed on immune-suppressive TAMs within the TME, where it functions as a negative regulator of inflammatory responses • Pionyr’s humanized IgG1 afucosylated monoclonal antibody (PY314) specifically binds human TREM2 and balances the TME (‘Myeloid Tuning’) by specifically depleting TREM2+ TAMs, via antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) •…Read more

day: Day One